| Original language | English (US) |
|---|---|
| Pages (from-to) | 750 |
| Number of pages | 1 |
| Journal | Proceedings of the American Association for Cancer Research |
| Volume | Vol. 22 |
| State | Published - 1981 |
ASJC Scopus subject areas
- Medicine(all)
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Phase I study of MVE-2 therapy in human cancer. / Powell, M. L.; Hersh, E. M.; Gutterman, J. U.
In: Proceedings of the American Association for Cancer Research, Vol. Vol. 22, 1981, p. 750.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Phase I study of MVE-2 therapy in human cancer
AU - Powell, M. L.
AU - Hersh, E. M.
AU - Gutterman, J. U.
N1 - Funding Information: M. Rosenblum, A. Rios, E. Hersh and T. Loo. The University of Texas System Cancer Center, M.D. Anderson Hospital, Houston, Tx. 77030 MVE-2 is a polyanlonic macromolecule with an average molecular weight of 15,500 daltons. In concert with its phase I clinical trial, we developed a high performance liquid chro-matographlc (HPLC) method for analysis of MVE-2 in biological fluids to study its pharmacokinetics. The lowest limits of detection of MVE-2 were lO~g/ml in plasma and 25~g/ml in urine. Pharmacology studies were performed on six patients with cancer who received MVE-2 as a l-hour infusion. Four patients received 650 mg/m 2 and 2 received 1000 mg/m 2 and 1500 mg/m 2 respectively. MVE-2 disappeared from the plasma exponentially and its pharmacoklnetics could best (r2-0.95) be described by the open one compartment mathemai-cal model. Plasma t½ ranged from 13-15 minutes and was independent of dose. The apparent volume distribution (Vd) was 220 ml/kp and the clearance rate was II.I ml/mln/kg. Although the agent was cleared rapidly, only 45Z of the dose was excreted in the urine 24 hours after administration with only small amounts of MVE-2 excreted in urine thereafter. In light of the fast clearance but relatively low urinary excretion of this agen~ these studies suggest that MVE-2 may be rapidly sequestered or metabolized in vlvo. Supported by NCI contract 6Rd-87185, Grant CA-29769, Biomedical Research Support Grant RR 5511 and a grant from Adria Laboratories.
PY - 1981
Y1 - 1981
UR - http://www.scopus.com/inward/record.url?scp=0019468164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019468164&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0019468164
VL - Vol. 22
SP - 750
JO - Proceedings of the American Association for Cancer Research
JF - Proceedings of the American Association for Cancer Research
ER -